Skip to main content
Full access
Erratum
Published Online: 3 November 2006

Erratum

In the article “Companies Desperately Seek Antidepressant Breakthrough” in the June 2 issue, the investigational antidepressant medication desvenlafaxine was incorrectly said to be under development by GlaxoSmithKline (GSk). The drug is actually under development by Wyeth, which also developed and markets venlafaxine (Effexor), the parent compound of desvenlafaxine. A chart accompanying the article correctly listed Wyeth as the developer. ▪

Information & Authors

Information

Published In

History

Published online: 3 November 2006
Published in print: November 3, 2006

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share